Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02016729
Title A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications

acute myeloid leukemia

Therapies

Trametinib

KRT-232

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Birmingham Alabama 35294 United States Details
Research Site Buffalo New York 14263 United States Details
Research Site Charlotte North Carolina 28204 United States Details
Research Site Salt Lake City Utah 84112 United States Details
Research Site Seattle Washington 98101 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field